Skip to main navigation Skip to search Skip to main content

HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms

  • C. H. Chen
  • , W. H. Chang
  • , K. Y. Su
  • , W. H. Ku
  • , G. C. Chang
  • , Q. S. Hong
  • , Y. J. Hsiao
  • , H. C. Chen
  • , H. Y. Chen
  • , R. Wu
  • , P. C. Yang
  • , J. J.W. Chen
  • , S. L. Yu*
    • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms'. Together they form a unique fingerprint.
Sort by

Biochemistry, Genetics and Molecular Biology

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science